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Introduction
Very little is presently known about the immunologic properties of human myoblasts and myotubes. Such knowledge is essential for myoblast transplantation, a potentially promising experimental therapy for hereditary muscle diseases, such as Duchenne muscular dystrophy (1) (2) (3) . Myoblast transplantation has been used successfully in a murine model ofmuscular dystrophy: Injection of normal myoblasts into dystrophic muscle of mdx mice led to myoblast fusion and expression of dystrophin by the mosaic muscle fibers (2, 3) . One of the potential problems ofthis therapy is allograft rejection (discussed in reference 1). We demonstrate here that cultured human myotubes can be efficiently killed by allospecific CD8+ cytotoxic T cells (CTL)' and by HLA-nonrestricted natural killer (NK) cells. These findings raise concern that also in vivo, transplanted human myoblasts may be attacked by the two different types of cytotoxic effector cells.
Methods
MAbs. Anti-CD3 (Leu-4), anti-CD8 (Leu-2a), anti-CD16 (Leu-l lb), and anti-CD56 (Leu-19) MAbs were purchased from Becton-Dickinson (Mountain View, CA). Anti-class I HLA MAb W6/32 was obtained from Sera-Lab (Hicksville, NY). For indirect immunofluorescence, biotinylated horse anti-mouse IgG and FITC-labeled avidin-D (both from Vector Laboratories, Burlingame, CA) were used as the secondary reagents. For functional studies, MAbs Leu-I lb and W6/32 were freed of azide by dialysis against PBS.
Target cells. K562 cells were obtained from the American Type Culture Collection, Rockville, MD. Human myoblasts and myotubes were cultured as described (4, 5) . Briefly, the myoblasts were grown in gelatin-coated culture dishes in Ham's F-10 medium containing 20% heat-inactivated FCS, 0.5% chick embryo extract (all from Gibco Laboratories, Grand Island, NY), 100 U/ml penicillin (Sigma Chemical Co., St. Louis, MO), 100 ug/ml streptomycin (Sigma), and 2 mM L-glutamine (Gibco Laboratories). The myoblast preparations used in the experiments were > 90% pure as assessed by immunostaining with MAb anti-Leu-19 that cross-reacts with the neural cell adhesion molecule N-CAM (6). To induce myotube differentiation, myoblasts were plated in a fusion-supporting medium (Dulbecco's modified Eagle medium containing 2% heat-inactivated horse serum (both from Gibco), 100 U/ml penicillin, and 100 ug/ml streptomycin). Under these conditions, fusion was usually complete after 4-5 d.
Effector cells. PBMC were isolated on Ficoll-Hypaque and fractionated into nonadherent PBMC by depleting plastic-adherent and nylon wool-adherent cells (7) . Nonadherent PBMC were depleted of NK cells by treatment with anti-Leu-l lb and C as suggested by the supplier. The NK cell-depleted preparations contained no residual Leu-l lb or Leu-19-reactive cells as assessed by FACS analysis and fluorescence microscopy. Alloreactive CD3+CD8+ T cell lines were generated in mixed lymphocyte culture with irradiated allogeneic PBMC and propagated by repeated stimulation with PHA and irradiated allogeneic PBMC (8) . The alloreactive CTL lines used in the experiments were > 95% CD3+CD8+CD16-CD56-as assessed by flow cytometry. Before use in cytotoxicity assays, the CTL were cultured for at least 7 d in lectin-free medium.
Flow cytometry. Analysis were performed with a FACS IV system (Becton-Dickinson).
Cytotoxicity assays. Cytotoxicity against K562 target cells was measured in a standard 4-h 5"Cr-release assay (7) . Cytotoxicity against myotubes was measured in an 8-h 5"Cr-release assay. Briefly, myoblasts were plated into gelatin-coated, flat-bottomed microwells at 5 X IO' cells per well. The myoblasts fused into myotubes within 6-8 d of culture. Each well was labeled with 6 ACi (Na)2 5"Cr 04 for 1 h, rinsed repeatedly, and the chromium-labeled myotubes were then used as targets. The cytotoxicity assays were done in triplicates. Maximal release was induced with 5% Triton X-100. Background release ranged from 10 to 24% of the maximal release. The mean percent specific cytotoxicity, c, was calculated for each set of triplicates according to c = 100 X (x-b)/(m -b) with x, mean experimental release; b, mean background release; m, mean maximal release.
Morphology. Interactions of living cells in culture were observed under phase optics. A grid of perpendicular lines was drawn on the outer surface of individual wells of a 24-well culture plate (Costar, Cambridge, MA) to help in the identification and sequential observation of individual myotubes. For immunoelectron microscopy, myotubes and CTL were co-cultured on Teflon membranes (9) using a modified ABC immunoperoxidase protocol (10). 1 h after initiation of co-culture, the cultures were placed on ice and treated with anti-CD8 MAb (10 Mg/ml) diluted in PBS containing 2% BSA, 10% heat-inactivated serum from AB+ donors, and 5% heat-inactivated horse serum (Gibco). After 30 min of incubation at 40C, the cultures were rinsed three times with ice-cold PBS, treated with 7.5 Mg/ml biotinylated horse anti-mouse IgG (Vector Laboratories) for 30 min at 4°C, rinsed three times with PBS, fixed with 1% glutaraldehyde buffered with 0.1 M Tris buffer (pH, 7.6) containing 25 mM hydroxylamine. Next, the cultures were treated with the avidin-biotin peroxidase complex (Vector) for 30 min at 25°C, rinsed with PBS for 20 min, treated with 0.01% hydrogen peroxide, 0.05% diaminobenzidine in 0.1 M Tris buffer (pH, 7.6) for 15 
Results
Cultured myotubes were killed by alloreactive CD3+CD8+ CD16-CD56-T cells (Fig. 1) . Lysis involved the recognition of allogeneic class I HLA molecules because it was completely inhibited with anti-class I HLA MAb W6/32 (Fig. 1) , and because autologous myotubes were not lysed (< 1% specific 5'Cr-release at an E/T ratio of 20:1). Furthermore, alloreactive T cells had no detectable NK activity against K-562 target cells (< 1% specific 5"Cr-release at an E/T ratio of 20:1).
We followed the stages of myotube lysis by sequential observation of individual myotubes under phase optics (Fig. 2) . The first stage was adhesion of T cells to myotubes (this became apparent within 30 min after adding the T cells). The second stage was incipient destruction and partial retraction of myotubes (1 h). The third stage was complete destruction and detachment (2 h). Immunoelectron microscopic analysis showed that the CD8+ CTL extended CD8+ spikelike projec- (Fig. 3) .
Not only were myotubes susceptible to lysis by alloreactive CTL, but also by freshly isolated allogeneic and autologous PBMC. The lysis of myotubes by PBMC was similar to the lysis ofthe NK-sensitive target K562 (Fig. 4) . The lysis was not due to cytotoxic macrophages because nylon wool-nonadherent, macrophage-depleted cells retained the cytotoxic potential (Fig. 5) . In contrast, the cytotoxicity was mediated by CD16+ natural killer cells because it was abrogated by depletion of CD 16+ cells with anti-Leu-l lb and C (Fig. 5) Myotubes constitutively express HLA-class I (5, 14) . This is a necessary but not sufficient precondition for allospecific recognition by CD8+ CTL. For example, mouse trophoblasts (15) highly susceptible to both types of cytotoxic effector cells represents a further exception. In this regard, it is important that human myotubes react with the anti- . This MAb reacts with CD56, an isoform of the neural cell adhesion molecule N-CAM (6) . N-CAM is a homotypic adhesion molecule of the Ig superfamily (21) . CD56 is also expressed on NK cells (12, 13) . There is evidence that CD56 is functionally involved in NK cell-mediated cytotoxicity against targets bearing N-CAM (22). As yet, we have no conclusive evidence that the killing of myotubes by NK cells can be inhibited with anti-CD56 MAb, but this question will be subject to further investigation. It is not known whether NK cells can attack normal myotubes in vivo. If regenerating myotubes in vivo were as susceptible to NK cell-mediated lysis as are cultured myotubes, normal muscle regeneration could not occur because the myotubes would be killed by autologous NK cells. One possibility Myotube target cells 60 is that myotubes are intrinsically more resistant to autologous NK cells in vivo. Regenerating muscle fibers are known to express high levels of N-CAM/CD56 in vivo (20) , so that N-CAM expression on myotubes is probably not a regulating factor. However, there may be other mechanisms that prevent the lysis of myoblasts and myotubes in vivo. The postulated regulatory factors (e.g., cytokines) may act on the level of effector cells, target cells, or both (reviewed in reference 13).
Our observations have obvious clinical implications for myoblast transplantation, an experimental strategy for the treatment of muscular dystrophy and other hereditary muscle diseases (1-3) . Injection of myoblasts from normal mouse or human muscle into growing or regenerating muscle of mdx mice, which represent a murine genetic homologue of human Duchenne muscular dystrophy (23, 24), led to substantial expression and correct localization of dystrophin in the injected muscle (1-3) . The transplanted normal myoblasts fused with host muscle fibers giving rise to "mosaic fibers" in which the normal dystrophin gene of the transplanted myonuclei was expressed in muscle fiber segments. Thus, the mosaic fibers were partially rescued from their biochemical defect and escaped fiber necrosis.
Obviously, numerous problems must be dealt with before this promising experimental therapy can be applied in human disease (discussed in reference 1). One of these problems is the possibility of allograft rejection. In one study, rejection was circumvented by using immunocompromised or tolerant host strains (2) . However, in another study (3) 
